Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70264 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Silvio Danese und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Ustekinumab, Colitis, Ulcerative, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson and Johnson.
Abstract (Originalsprache)
Background
Achievement of disease clearance (simultaneous symptomatic remission and histo‐endoscopic mucosal improvement [HEMI]) following induction therapy may lead to better long‐term outcomes in ulcerative colitis (UC).
Aim
To evaluate disease clearance in the phase 3 UNIFI program and its association with long‐term outcomes.
Methods
UNIFI comprised randomised, placebo‐controlled induction and maintenance studies and a long‐term extension, which evaluated intravenous ustekinumab induction (130 mg or ~6 mg/kg) and subcutaneous ustekinumab maintenance therapy (90 mg every 8 or 12 weeks) through 4 years in patients with UC.
Results
Disease clearance was achieved by 5.9%, 15.2% and 15.1% of patients 8 weeks after placebo or ustekinumab 130 mg or ~6 mg/kg induction, respectively. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who did or did not achieve disease clearance 8 weeks after induction, 63.6% and 35.2% (nominal p < 0.001), respectively, achieved clinical remission (Mayo score ≤ 2, no individual subscore > 1) at Week 44. Among ustekinumab induction responders randomised to ustekinumab maintenance therapy who achieved disease clearance, symptomatic remission without HEMI, or neither symptomatic remission nor HEMI 8 weeks after induction, 73.4%, 53.5% (nominal p = 0.002) and 45.1% (nominal p < 0.001), respectively, achieved symptomatic remission (Mayo stool frequency subscore 0/1, rectal bleeding subscore 0) and 58.2%, 46.5% (nominal p = 0.09) and 42.7% (nominal p = 0.05), respectively, achieved Inflammatory Bowel Disease Questionnaire remission (score ≥ 170) at Week 200.
Conclusions
Patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long‐term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. Trial Registration NCT02407236
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
- Department of Gastroenterology, Concord Repatriation General Hospital, Concord, New South Wales, Australia.
- Department of Gastroenterology, Macquarie University Hospital, Sydney, New South Wales, Australia.
- Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Biostatistics, Johnson & Johnson, Horsham, Pennsylvania, USA.
- Immunology, Johnson & Johnson, Spring House, Pennsylvania, USA.
ORCID-Profile: Silvio Danese, Rupert W Leong, Laurent Peyrin-Biroulet
Förderung
- Johnson and Johnson
Zitieren
APA
Danese, S., Leong, R. W., Sands, B. E., Ma, T., Marano, C., & Peyrin-Biroulet, L. (2025). Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70264
Vancouver
Danese S, Leong RW, Sands BE, Ma T, Marano C, Peyrin-Biroulet L. Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70264
BibTeX
@article{Danese2025,
author = {Danese, Silvio and Leong, Rupert W and Sands, Bruce E and Ma, Tony and Marano, Colleen and Peyrin-Biroulet, Laurent},
title = {Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70264}
}
EUVIMED